Don't Let Shkreli Hijack Pharma's Reputation
This article was originally published in Scrip
This week Martin Shkreli and his devil-may-care attitude to price gouging has effectively taken the delicate hope for an informed public debate about how to balance society's need for medicines and its ability to pay with the R&D risks and costs and profit motive of the pharmaceutical industry, and smashed it to smithereens.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.